PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling
Journal
British Journal of Pharmacology
Journal Volume
171
Journal Issue
24
Pages
5728-5742
Date Issued
2014
Author(s)
Abstract
Background and Purpose Angiogenesis contributes to coronary heart disease, immune disorders and numerous malignancies. VEGF-A and its receptors (VEGFRs) play a pivotal role in regulating angiogenesis. In an effort to discover more effective inhibitors of tumour angiogenesis, we have analysed the actions of a novel anthraquinone derivative, PPemd26, and explored its anti-angiogenic mechanisms.Experimental Approach The effects of PPemd26 were evaluated in vitro using HUVEC cultures to assess proliferation, migration, invasion and tube formation. Immunoblotting was used to analyse phosphorylation of signalling kinases. Effects in vivo were assayed using Matrigel plug and xenograft mouse models.Key Results PPemd26 significantly inhibited VEGF-A-induced proliferation, migration, invasion and tube formation of HUVECs. PPemd26 also attenuated VEGF-A-induced microvessel sprouting from rat aortic rings ex vivo and suppressed formation of new blood vessels in implanted Matrigel plugs in models of angiogenesis in vivo. In addition, PPemd26 inhibited VEGF-A-induced phosphorylation of VEGFR2 and its downstream protein kinases including Akt, focal adhesion kinase, ERK and Src. Furthermore, systemic administration of PPemd26 suppressed the growth of s.c. xenografts of human colon carcinoma in vivo. Histochemical analysis of the xenografts revealed a marked reduction in stainingfor the vascular marker CD31 and proliferation marker Ki-67.Conclusions and Implications This study provides evidence that PPemd26 suppressed tumour angiogenesis through inhibiting VEGFR2 signalling pathways, suggesting that PPemd26 is a potential drug candidate for developing anti-angiogenic agents for the treatment of cancer and angiogenesis-related diseases. ? 2014 The British Pharmacological Society.
SDGs
Other Subjects
1,8 dihydroxy 4,5 dinitroanthraquinone; angiogenesis inhibitor; CD31 antigen; focal adhesion kinase; Ki 67 antigen; mitogen activated protein kinase 1; mitogen activated protein kinase 3; protein kinase B; protein kinase p60; sunitinib; unclassified drug; vasculotropin A; vasculotropin receptor 2; 1,8-dinitro-4,5-dihydroxyanthraquinone; angiogenesis inhibitor; anthraquinone derivative; focal adhesion kinase; mitogen activated protein kinase; protein kinase B; protein kinase p60; vascular endothelial growth factor receptor-2, human; vasculotropin A; vasculotropin receptor 2; VEGFA protein, human; animal experiment; animal model; animal tissue; antiangiogenic activity; antiproliferative activity; Article; cancer inhibition; cell growth; cell invasion; cell migration; cell proliferation; cell viability; concentration response; controlled study; drug effect; enzyme activity; enzyme phosphorylation; histochemistry; IC50; immunoblotting; in vitro study; in vivo study; male; mouse; nonhuman; protein binding; rat; signal transduction; treatment duration; tumor vascularization; tumor volume; angiogenesis; animal; aorta; carcinoma; cell motion; cell survival; colon tumor; drug effects; drug screening; growth, development and aging; human; metabolism; microvasculature; signal transduction; umbilical vein endothelial cell; Angiogenesis Inhibitors; Animals; Anthraquinones; Aorta; Carcinoma; Cell Movement; Cell Proliferation; Cell Survival; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Mice; Microvessels; Neovascularization, Physiologic; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Rats; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays
Type
journal article